Clinical Trial Detail

NCT ID NCT03487666
Title OXEL: Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Georgetown University
Indications

triple-receptor negative breast cancer

Therapies

Capecitabine + Nivolumab

Capecitabine

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST